checkAd
    Startseite > Aktien > Pharvaris > Nachrichten
    Pharvaris Aktie
    19,800
     
    EUR
    +2,06 %
    +0,400 EUR
    Letzter Kurs 10.05.24 Tradegate
    19,600
     
    EUR
    103 STK
    Geldkurs 08:00:17
    20,200
     
    EUR
    99 STK
    Briefkurs 08:00:17
    ISIN: NL00150005Y4 · WKN: A2QNWS · SYM: 9EN · Niederlande

    Neueste Nachrichten

    Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
    08.05.24 · globenewswire · Pharvaris
    Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    10.04.24 · globenewswire · Pharvaris
    Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
    10.04.24 · globenewswire · Pharvaris
    Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
    04.04.24 · globenewswire · Pharvaris
    Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
    18.03.24 · globenewswire · Pharvaris
    Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
    06.03.24 · globenewswire · Pharvaris
    Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
    05.03.24 · globenewswire · Pharvaris
    Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
    22.02.24 · globenewswire · Pharvaris
    Pharvaris Announces Extraordinary Meeting of Shareholders
    16.02.24 · globenewswire · Pharvaris
    Pharvaris to Present at the WSAAI Annual Meeting 2024
    26.01.24 · globenewswire · Pharvaris
    Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
    22.01.24 · globenewswire · Pharvaris
    Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
    05.01.24 · globenewswire · Pharvaris